119141-88-7 | Esomeprazole (C₁₇H₁₉N₃O₃S)

Chemical type

• Proton pump inhibitor (PPI)

^[1]

• Proton pump inhibitor (PPI)
• Chiral drug (S-enantiomer of omeprazole)

^[2]

Key properties

• Inhibits H⁺/K⁺-ATPase in gastric parietal cells
• Acid suppression dependent on CYP2C19 genotype
• Previously used in rifabutin-based regimens

^[1]

• Potent inhibitor of organic cation transporter 2 (OCT2)
• Reduces oxaliplatin uptake into dorsal root ganglion (DRG) neurons
• Exhibits antioxidant effects
• More stable metabolism compared with racemic omeprazole
• Selective inhibition of OCT2 with minimal inhibition of MATE1 transporter

^[2]

• Acid suppression in H. pylori eradication therapy
• Treatment of acid-related gastrointestinal disorders

^[1]

• Treatment of gastroesophageal acid-related disorders
• Investigated as a protective agent against oxaliplatin-induced peripheral neuropathy (OIPN)
• Potential adjuvant drug in chemotherapy to reduce neurotoxicity

^[2]

Classification by use

• Chemicals used as gastric acid inhibitors
• Chemicals used in gastrointestinal disease treatment

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial, The Lancet Regional Health - Western Pacific, Volume 68, March 2026, 101815
2. [Cite:2] Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice, European Journal of Pharmaceutical Sciences, Volume 214, 1 November 2025, 107309